Bukwang Pharmaceutical Co. Ltd.

South Korean pharma leader Bukwang produces oral solids, injectables and nutraceuticals. With a robust domestic market, its pipeline features Lurasidone for schizophrenia, JM‑010 for Parkinson’s dyskinesia and SOL‑804 for metastatic prostate cancer, driving global expansion.

Headquarters: South Korea (KOR)

Bukwang Pharmaceutical Co. Ltd. Logo
Company Profile
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
003000 Bukwang Pharmaceutical Co. Ltd.
Cap: 389.2B
EQUITY KSC KRW KR7003000007 Active
📈
Home Login